Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R)

Cancer Biology and Therapy

Volumn 7, Issue 7, 2008, Pages 1024-1032

  Andjelkovic, Tijana ^a   Pesic, Milica ^a   Bankovic, Jasna ^a   Tanic, Nikola ^a   Markovic, Ivanka D ^b   Ruzdijic, Sabera ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Curcumin; Drug combination; Gene expression; Lung carcinoma; Multidrug resistance; p53 status; Sulfinosine

Indexed keywords

CURCUMIN; SULFINOSINE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL LINE; CYTOTOXICITY; DNA SEQUENCE; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; NCI H460 R CELL LINE; P53 GENE; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

EID: 47949104284     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.7.6036     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
2. Gottesman MM. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993; 53:747-54.
3. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000; 65:95-106.
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
5. Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis. Oncogene 2002; 21:6898-907.
6. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292:470-84.
7. Revankar GR, Hanna NB, Imamura N, Lewis AF, Larson SB, Finch RA, Avery TL, Robins RK. Synthesis and in vivo antitumor activity of 2-amino-9H-purine-6- sulfenamide, -sulfinamide, and -sulfonamide and related purine ribonucleosides. J Med Chem 1990; 33:121-8.
8. Avery TL, Finch RA, Vasquez KM, Radparvar S, Hanna NB, Revankar GR, Robins RK. Chemotherapeutic characterization in mice of 2-amino-9-beta-D- ribofuranosylpurine-6-sulfinamide (sulfinosine), a novel purine nucleoside with unique antitumor properties. Cancer Res 1990; 50:2625-30.
9. Milosevic J, Kanazir S, Medic-Mijacevic L, Pejanovic V, Stokic Z, Konjevic G, Rakic L, Ruzdijic S. Sulfinosine-induced cell growth inhibition and apoptosis in human lung carcinomas in vitro. Invest New Drugs 2002; 20:229-40.
10. Jankovic D, Pesic M, Markovic J, Kanazir S, Markovic I, Rakic L, Ruzdijic S. The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro. Invest New Drugs 2006; 24:15-25.
11. Fujitaki JM, Nord LD, Willis RC. Cellular metabolism of the antitumor nucleoside, sulfinosine, 2-amino-9-(β-D-ribofuranosyl)purine-6-sulfinamide. Proc Am Assoc Cancer Res 1989; 30:596.
12. Pesic M, Markovic JZ, Jankovic D, Kanazir S, Markovic ID, Rakic L, Ruzdijic S. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother 2006; 18:66-73.
13. Dorai T, Aggarwal BB. Role of chemopreventive agents in cancer therapy. Cancer Lett 2004; 215:129-40.
14. Limtrakul P. Curcumin as chemosensitizer. Adv Exp Med Biol 2007; 595:269-300.
15. Sambrook J, Fritsch EF, Maniatis T. Analysis and cloning of eucaryotic genomic DNA. In: Nolan C, ed. Molecular cloning: a laboratory manual. Second edition. New York: Cold Spring Harbor Laboratory Press, USA 1982; 16-19.
16. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86:2766-70.
17. Sakai E, Rikimaru K, Ueda M, Matsumoto Y, Ishii N, Enomoto S, Yamamoto H, Tsuchida N. The p53 tumor-suppressor gene and ras oncogene mutations in oral squamous-cell carcinoma. Int J Cancer 1992; 52:867-72.
18. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-12.
19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
20. Peters GJ, Van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 2000; 87:227-53.
21. Bosch S, Siavoshian S, Jacquot C, Tomasoni C, Dabouis G, Elanbaloussi Y, Leneel T, More MT, Roussakis C. Correlation between multidrug resistance and the degree of differentiation of non-small-cell bronchopulmonary carcinoma (NSCLC) in vitro and in vivo. Anticancer Res 1997; 17:4595-8.
22. O'Driscoll L, Daly C, Saleh M, Clynes M. The use of reverse transcriptase-polymerase chain reaction (RT-PCR) to investigate specific gene expression in multidrug-resistant cells. Cytotechnology 1993; 12:289-314.
23. Chadderton T, Wilson C, Bewick M, Gluck S. Evaluation of three rapid RNA extraction reagents: relevance for use in RT-PCR's and measurement of low level gene expression in clinical samples. Cell Mol Biol (Noisy-le-grand) 1997; 43:1227-34.
24. Wong H, Anderson WD, Cheng T, Riabowol KT. Monitoring mRNA expression by polymerase chain reaction: the "primer-dropping" method. Anal Biochem 1994; 223:251-8.
25. Ponte P, Ng SY, Engel J, Gunning P, Kedes L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res 1984; 12:1687-96.
26. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104:263-9.
27. Perdomo JA, Naomoto Y, Haisa M, Fujiwara T, Hamada M, Yasuoka Y, Tanaka N. In vivo influence of p53 status on proliferation and chemoradiosensitivity in non-small-cell lung cancer. J Cancer Res Clin Oncol 1998; 124:10-8.
28. Tang XQ, Bi H, Feng JQ, Cao JG. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacol Sin 2005; 26:1009-16.
29. Cantero G, Pastor N, Mateos S, Campanella C, Cortes F. Cisplatin-induced endoreduplication in CHO cells: DNA damage and inhibition of topoisomerase II. Mutat Res 2006; 599:160-6.
30. 2 blocks and their significance to the mechanism of cytotoxicity. Cancer Res 1980; 40:1458-62.
31. Srivastava RK, Chen Q, Siddiqui I, Sarva K, Shankar S. Linkage of curcumin-induced cell cycle arrest and apoptosis by cyclin-dependent kinase inhibitor p21(/WAF1/CIP1). Cell Cycle 2007; 6:2953-61.
32. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25.
33. Van Erk MJ, Teuling E, Staal YC, Huybers S, Van Bladeren PJ, Aarts JM, Van Ommen B. Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells. J Carcinog 2004; 3:8.
34. Volm M, Mattern J, Samsel B. Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-pi in human lung tumors. Cancer 1992; 70:764-9.
35. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255:459-62.
36. Johnson RA, Ince TA, Scotto KW. Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 2001; 276:27716-20.
37. Galimberti S, Marchetti A, Buttitta F, Carnicelli V, Pellegrini S, Bevilacqua G, Petrini M. Multidrug resistance related genes and p53 expression in human non small cell lung cancer. Anticancer Res 1998; 18:2973-6.
38. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 2002; 64:573-82.
39. Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, Tima S, Chanarat P, Limtrakul P. Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells. Arch Pharm Res 2006; 29:866-73.
40. Choi BH, Kim CG, Lim Y, Shin SY, Lee YH. Curcumin downregulates the multidrugresistance mdr1b gene by inhibiting the PI3K/Akt/NFkappaB pathway. Cancer Lett 2008; 259:111-8.
41. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54:4313-20.
42. Nakanishi Y, Kawasaki M, Bai F, Takayama K, Pei XH, Takano K, Inoue K, Osaki S, Hara N, Kiyohara C. Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer. Oncology 1999; 57:318-23.
43. Duvoix A, Morceau F, Delhalle S, Schmitz M, Schnekenburger M, Galteau MM, Dicato M, Diederich M. Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. Biochem Pharmacol 2003; 66:1475-83.
44. Giaccone G, Gazdar AF, Beck H, Zunino F, Capranico G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 1992; 52:1666-74.
45. Sandri MI, Isaacs RJ, Ongkeko WM, Harris AL, Hickson ID, Broggini M, Vikhanskaya F. p53 regulates the minimal promoter of the human topoisomerase IIalpha gene. Nucleic Acids Res 1996; 24:4464-70.
46. Wang Q, Zambetti GP, Suttle DP. Inhibition of DNA topoisomerase IIalpha gene expression by the p53 tumor suppressor. Mol Cell Biol 1997; 17:389-97.
47. Liu D, Huang CL, Kameyama K, Hayashi E, Yamauchi A, Sumitomo S, Yokomise H. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients. Cancer 2002; 94:2239-47.
48. Chen HW, Yu SL, Chen JJ, Li HN, Lin YC, Yao PL, Chou HY, Chien CT, Chen WJ, Lee YT, Yang PC. Anti-invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysis. Mol Pharmacol 2004; 65:99-110.
49. Wilson CS, Medeiros LJ, Lai R, Butch AW, McCourty A, Kelly K, Brynes RK. DNA topoisomerase IIalpha in multiple myeloma. a marker of cell proliferation and not drug resistance. Mod Pathol 2001; 14:886-91.
50. Crabtree GW, Finch RA, Vasquez KM, et al. Cysteine and glutathione competition for adduct formation with 2-amino-9-(β-D-ribofuranosyl)purine- 6-sulfinamide (sulfinosine, fin) modulates therapeutic efficacy. Proc Am Assoc Cancer Res 1989; 30:597.
51. Riley TA, Finch RA, Vasquez KM, et al. Isolation, identification, synthesis and therapeutic evaluation of selected metabolites of sulfinosine, a novel purine nucleoside analog active against thiopurine refractory experimental leukemia. Proc Am Assoc Cancer Res 1989; 30:599.
52. Arrigo AP. Gene expression and the thiol redox state. Free Radic Biol Med 1999; 27:936-44.
53. Sundseth R, MacDonald G, Ting J, King AC. DNA elements recognizing NF-Y and Sp1 regulate the human multidrug-resistance gene promoter. Mol Pharmacol 1997; 51:963-71.
54. Magan N, Szremska AP, Isaacs RJ, Stowell KM. Modulation of DNA topoisomerase IIalpha promoter activity by members of the Sp (specificity protein) and NF-Y (nuclear factor Y) families of transcription factors. Biochem J 2003; 374:723-9.